Table 2.
Price information of PD-1 and PD-L1 approved in China and the USA.
| Drug Name | Licensee | Price/dollars | Specification/mg | Dose/mg | Frequency | Total times/Year | Annual cost/10,000 dollars |
|---|---|---|---|---|---|---|---|
| Camrelizumab | Hengrui | China:3114 | 200 | 200 | q3w | 17 | China:5.3 |
| toripalimab | Junshi | China:1132 | 240 | 240 | q2w | 26 | China:2.9 |
| tislelizumab | BeiGene | China:1681 | 100 | 200 | q3w | 17 | China:5.7 |
| Sintilimab | Innovent | China:1233 | 100 | 200 | q3w | 17 | China:4.2 |
| Penpulimab | Akeso/Chaitai | China:767 | 100 | 200 | q2w | 26 | China:4.0 |
| Zimberelimab | Gloria/Wuxi | China:519 | 120 | 120 | q2w | 26 | China:1.3 |
| Envafolimab | Simcere/3D Med | China:940 | 200 | 200 | qw | 52 | China:4.9 |
| Pembrolizumab | MSD | China:2818 US:5102 |
100 | 200 | q3w | 17 | China:9.6 US:17.3 |
| Nivolumab | BMS | China:1456 US:3697 |
100 | 200 | q2w | 26 | China:7.6 US:19.2 |
| Atezolizumab | Genentech. | China:5158 US:9411 |
1200 | 1200 | q3w | 17 | China:8.8 US:16.0 |
| Durvalumab | AstraZeneca | China:2844 US:3697 |
500 | 500 | q2w | 26 | China:7.4 US:9.6 |
| Avelumab | Emd Serono | US:1692 | 200 | 600 | q2w | 26 | US:13.2 |
| Cemiplimab | Regeneron | US:9362 | 350 | 350 | q3w | 17 | US:15.9 |
| Dostarlimab | GSK | US:10304 | 500 | 500 | q3w | 17 | US:17.5 |